These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 26850977)

  • 1. Myasthenia gravis exacerbation after discontinuing mycophenolate: A single-center cohort study.
    Oskarsson B; Rocke DM; Dengel K; Richman DP
    Neurology; 2016 Mar; 86(12):1159-63. PubMed ID: 26850977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can mycophenolate mofetil be tapered safely in myasthenia gravis? A retrospective, multicenter analysis.
    Hobson-Webb LD; Hehir M; Crum B; Visser A; Sanders D; Burns TM
    Muscle Nerve; 2015 Aug; 52(2):211-5. PubMed ID: 25906756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of mycophenolate mofetil as a rescue agent in the treatment of severe generalized myasthenia gravis in three dogs.
    Abelson AL; Shelton GD; Whelan MF; Cornejo L; Shaw S; O'Toole TE
    J Vet Emerg Crit Care (San Antonio); 2009 Aug; 19(4):369-74. PubMed ID: 25164637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: outcomes in 102 patients.
    Hehir MK; Burns TM; Alpers J; Conaway MR; Sawa M; Sanders DB
    Muscle Nerve; 2010 May; 41(5):593-8. PubMed ID: 20405499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis.
    Sanders DB; Hart IK; Mantegazza R; Shukla SS; Siddiqi ZA; De Baets MH; Melms A; Nicolle MW; Solomons N; Richman DP
    Neurology; 2008 Aug; 71(6):400-6. PubMed ID: 18434638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mycophenolate mofetil in the therapy of severe myasthenia gravis.
    Schneider C; Gold R; Reiners K; Toyka KV
    Eur Neurol; 2001; 46(2):79-82. PubMed ID: 11528156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mycophenolate mofetil treatment in dogs with serologically diagnosed acquired myasthenia gravis: 27 cases (1999-2008).
    Dewey CW; Cerda-Gonzalez S; Fletcher DJ; Harb-Hauser MF; Levine JM; Badgley BL; Olby NJ; Shelton GD
    J Am Vet Med Assoc; 2010 Mar; 236(6):664-8. PubMed ID: 20225980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability.
    Meriggioli MN; Ciafaloni E; Al-Hayk KA; Rowin J; Tucker-Lipscomb B; Massey JM; Sanders DB
    Neurology; 2003 Nov; 61(10):1438-40. PubMed ID: 14638974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mycophenolate mofetil as second line immunosuppressant in Myasthenia gravis--a long-term prospective open-label study.
    Hanisch F; Wendt M; Zierz S
    Eur J Med Res; 2009 Aug; 14(8):364-6. PubMed ID: 19666397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis.
    Muscle Study Group
    Neurology; 2008 Aug; 71(6):394-9. PubMed ID: 18434639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of myasthenia gravis with mycophenolate mofetil: a case report.
    Meriggioli MN; Rowin J
    Muscle Nerve; 2000 Aug; 23(8):1287-9. PubMed ID: 10918271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mycophenolate mofetil for myasthenia gravis: an open-label pilot study.
    Ciafaloni E; Massey JM; Tucker-Lipscomb B; Sanders DB
    Neurology; 2001 Jan; 56(1):97-9. PubMed ID: 11148243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mycophenolate mofetil in myasthenia gravis: the unanswered question.
    Phan C; Sanders DB; Siddiqi ZA
    Expert Opin Pharmacother; 2008 Oct; 9(14):2545-51. PubMed ID: 18778192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mycophenolate mofetil versus enteric-coated mycophenolate sodium: a large, single-center comparison of dose adjustments and outcomes in kidney transplant recipients.
    Sollinger HW; Sundberg AK; Leverson G; Voss BJ; Pirsch JD
    Transplantation; 2010 Feb; 89(4):446-51. PubMed ID: 20177347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opportunistic infections in myasthenia gravis treated with mycophenolate mofetil.
    Termsarasab P; Katirji B
    J Neuroimmunol; 2012 Aug; 249(1-2):83-5. PubMed ID: 22613699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of a standard-dose prednisone regimen and mycophenolate mofetil combined with a lower prednisone dose in Chinese adults with idiopathic nephrotic syndrome who were carriers of hepatitis B surface antigen: a prospective cohort study.
    Li X; Tian J; Wu J; He Q; Li H; Han F; Li Q; Chen Y; Ni Q; Chen J
    Clin Ther; 2009 Apr; 31(4):741-50. PubMed ID: 19446147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mycophenolate mofetil in systemic lupus erythematosus: results from a retrospective study in a large monocentric cohort and review of the literature.
    Conti F; Ceccarelli F; Perricone C; Massaro L; Cipriano E; Pacucci VA; Truglia S; Miranda F; Morello F; Alessandri C; Spinelli FR; Valesini G
    Immunol Res; 2014 Dec; 60(2-3):270-6. PubMed ID: 25468307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mycophenolate mofetil - as an adjunctive immunosuppressive therapy in refractory myasthenia gravis: The Singapore experience.
    Prakash KM; Ratnagopal P; Puvanendran K; Lo YL
    J Clin Neurosci; 2007 Mar; 14(3):278-81. PubMed ID: 16597503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases.
    Chaudhry V; Cornblath DR; Griffin JW; O'Brien R; Drachman DB
    Neurology; 2001 Jan; 56(1):94-6. PubMed ID: 11148242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lessons from two trials of mycophenolate mofetil in myasthenia gravis.
    Sanders DB; Siddiqi ZA
    Ann N Y Acad Sci; 2008; 1132():249-53. PubMed ID: 18567876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.